Cholinesterase inhibitors: new roles and therapeutic alternatives.

An important aspect of brain cholinesterase function is related to enzymatic differences. The brain of mammals contains two major forms of cholinesterases: acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). The two forms differ genetically, structurally and for their kinetics. Butyrylcholine is not a physiological substrate in mammalian brain which makes the function of BuChE of difficult interpretation. In human brain, BuChE is found in neurons and glial cells as well as in neuritic plaques and tangles in Alzheimer disease (AD) patients. While AChE activity decreases progressively in the brain of AD patients, BuChE activity shows some increase. In order to study the function of BuChE, we perfused intracortically the rat brain with a selective BuChE inhibitor and found that extracellular acetylcholine increased 15 fold from 5 to 75nM concentrations with little cholinergic side effects in the animal. Based on these data and on clinical data showing a relation between CSF BuChE inhibition and cognitive function in AD patients, we postulated that two pools of cholinesterases may be present in brain, the first mainly neuronal and AChE dependent and the second mainly glial and BuChE dependent. The two pools show different kinetic properties with regard to regulation of ACh concentration in brain and can be separated with selective inhibitors. Within particular conditions, such as in mice nullizygote for AChE or in AD patients at advanced stages of the disease, BuChE may replace AChE in hydrolyzing brain acetylcholine. Based on the changes of ChE activity in the brain of AD patients, a rational indication of selective BuChEI (or of mixed double function inhibitors) is the treatment of advanced cases. A second novel aspect of ChEI therapy is the emerging of new indications which include various forms of dementia such as dementia with Lewy Bodies, Down Syndrome, vascular dementia and Parkinson Dementia. Clinical results demonstrate examples of versatility of cholinergic enhancement.

[1]  M. Emre.  Switching cholinesterase inhibitors in patients with Alzheimer's disease. , 2002, International journal of clinical practice. Supplement.

[2]  R. Anand,et al.  An efficacy and safety analysis of Exelon® in Alzheimer’s disease patients with concurrent vascular risk factors , 2000, European journal of neurology.

[3]  M. Mesulam,et al.  Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine , 2002, Neuroscience.

[4]  M. Bayley,et al.  Open-label study of donepezil in traumatic brain injury. , 2001, Archives of physical medicine and rehabilitation.

[5]  K. Rockwood,et al.  Butyrylcholinesterase and Cognitive Function , 2001, International Psychogeriatrics.

[6]  E. Giacobini,et al.  Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit , 2002, Journal of Neural Transmission.

[7]  N. Greig,et al.  Phenserine regulates translation of β-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. Morris,et al.  Panel discussion:recommendations for prescribers , 2001 .

[9]  M N Rossor,et al.  Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease. A longitudinal prospective study. , 1998, Brain : a journal of neurology.

[10]  N. Slatkin,et al.  Donepezil in the treatment of opioid-induced sedation: report of six cases. , 2001, Journal of pain and symptom management.

[11]  A. Lerner,et al.  Adverse effects of donepezil in treating Alzheimer's disease associated with Down's syndrome. , 1999, The American journal of psychiatry.

[12]  J. Rabey,et al.  The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia , 2000, Neurobiology of Aging.

[13]  K. Krishnan,et al.  Cholinergic therapy for Down's syndrome , 1999, The Lancet.

[14]  N. Greig,et al.  Butyrylcholinesterase: a new therapeutic target in AD treatment? , 2001 .

[15]  E. Perry,et al.  CHANGES IN BRAIN CHOLINESTERASES IN SENILE DEMENTIA OF ALZHEIMER TYPE , 1978, Neuropathology and applied neurobiology.

[16]  I. Lott,et al.  Down syndrome and Alzheimer disease: response to donepezil. , 2002, Archives of neurology.

[17]  R. Moretti,et al.  Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow‐up , 2001, European journal of neurology.

[18]  V. Prasher,et al.  A 24‐week, double‐blind, placebo‐controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease—pilot study , 2002, International journal of geriatric psychiatry.

[19]  C. Geula,et al.  Neuroglial cholinesterases in the normal brain and in Alzheimer's disease: Relationship to plaques, tangles, and patterns of selective vulnerability , 1993, Annals of neurology.

[20]  E. Shohami,et al.  Cerebro-protective effects of ENA713, a novel acetylcholinesterase inhibitor, in closed head injury in the rat , 1998, Brain Research.

[21]  K. Krishnan,et al.  Donepezil for Down's syndrome. , 2001, The American journal of psychiatry.

[22]  T. McRae,et al.  Comments on Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease who Failed to Benefit from Treatment with Donepezil , 2002, Current medical research and opinion.

[23]  C. Geula,et al.  Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia , 1994, Annals of neurology.

[24]  S. Schultz,et al.  Donepezil in the Treatment of Cognitive Dysfunction Associated with Traumatic Brain Injury , 2000, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[25]  Serge Gauthier,et al.  Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial , 2002, The Lancet.

[26]  W. Burke,et al.  Donepezil Improves Symptoms of Delirium in Dementia: Implications for Future Research , 1998, Journal of geriatric psychiatry and neurology.

[27]  Ann Silver,et al.  The biology of cholinesterases , 1974 .

[28]  P. Fischer.  Successful treatment of nonanticholinergic delirium with a cholinesterase inhibitor. , 2001, Journal of clinical psychopharmacology.

[29]  S. Lichtman,et al.  Donepezil medicated memory improvement in traumatic brain injury during post acute rehabilitation. , 1998, Brain injury.

[30]  Murat Emre,et al.  Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study , 2000, The Lancet.

[31]  E. Giacobini,et al.  Cholinesterase inhibitor effects on neurotransmitters in rat cortex in vivo. , 1994, The Journal of pharmacology and experimental therapeutics.

[32]  B. Vellas,et al.  Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease who Failed to Benefit from Treatment with Donepezil , 2002, Current medical research and opinion.

[33]  E. Giacobini.  Selective Inhibitors of Butyrylcholinesterase , 2001 .

[34]  M. Emre,et al.  Therapeutic Effects of an Acetylcholinesterase Inhibitor (Donepezil) on Memory in Wernicke–Korsakoff's Disease , 2002, Clinical neuropharmacology.

[35]  R. Bullock,et al.  Switching cholinesterase inhibitor therapy in Alzheimer's disease—donepezil to rivastigmine, is it worth it? , 2002, International journal of geriatric psychiatry.

[36]  C. Ghelardini,et al.  Central Cholinergic Challenging of Migraine by Testing Second‐Generation Anticholinesterase Drugs , 2002, Headache.

[37]  H. Levin,et al.  Effects of oral physostigmine and lecithin on memory and attention in closed head-injured patients. , 1986, Central nervous system trauma : journal of the American Paralysis Association.

[38]  J. Thornby,et al.  Feasibility of treating mild cognitive impairment withcholinesterase inhibitors , 2002, International journal of geriatric psychiatry.

[39]  T. Ohmori,et al.  A case of Korsakoff's syndrome improved by high doses of donepezil. , 2001, Alcohol and alcoholism.

[40]  L. Gerstman,et al.  Selective effects of cholinergic treatment on verbal memory in posttraumatic amnesia. , 1982, Journal of clinical neuropsychology.